Literature DB >> 27558550

Right Ventricular Pressure Overload and Pathophysiology of Growing Porcine Biomodel.

Jiri Kobr1, Zdenek Slavik2, Hideki Uemura2, Imran Saeed2, Anke Furck2, Katerina Pizingerová3, Jiri Fremuth3, Zbynek Tonar4.   

Abstract

The primary objective was to create a clinically relevant model of right ventricular hypertension and to study right ventricular myocardial pathophysiology in growing organism. The secondary objective was to analyse the effect of oral enoximone (phosphodiesterase inhibitor) therapy on right ventricular haemodynamic parameters and myocardial changes in biomodel of right ventricular hypertension. The study included a total of 12 piglets of 42 days of age. Under general anaesthesia, pulmonary artery banding (PAB) was performed surgically to constrict the main pulmonary artery to about 70-80 % of its original dimension. The study presented two groups of animals labelled C (control animals with PAB; n = 8) and E (animals with PAB and oral administration of enoximone; n = 4). Direct pressure and echocardiographic measurements were taken during operation (time-1), and again at 40 days after surgery (time-2). The animals were killed, and tissue samples from the heart chambers were collected for quantitative morphological assessment. Statistical analysis was performed on all acquired data. At time-2, the median weight of animals doubled and the median systolic pressure gradient across the PAB increased (46.59 ± 15.87 mmHg vs. 20.29 ± 5.76 mmHg; p < 0.001). Changes in haemodynamic parameters were compatible with right ventricular diastolic dysfunction in all the animals. Apoptosis, tissue proliferation and fibrosis were identified in all the myocardial tissue samples. Right ventricular pressure overload leads to increased apoptosis of cardiac myocytes, proliferation and myocardial fibrosis. Our study did not show evidence of haemodynamic benefit or myocardial protective effect of oral enoximone treatment.

Entities:  

Keywords:  Enoximone; Piglets; Pressure overload; Pulmonary hypertension

Mesh:

Year:  2016        PMID: 27558550     DOI: 10.1007/s00246-016-1463-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  21 in total

Review 1.  Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II.

Authors:  C R Taylor; R M Levenson
Journal:  Histopathology       Date:  2006-10       Impact factor: 5.087

2.  The treatment of certain congenital malformations of the heart by the creation of pulmonic stenosis to reduce pulmonary hypertension and excessive pulmonary blood flow; a preliminary report.

Authors:  W H MULLER; J F DANIMANN
Journal:  Surg Gynecol Obstet       Date:  1952-08

Review 3.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  VersaCount: customizable manual tally software for cell counting.

Authors:  Charles C Kim; Joseph L Derisi
Journal:  Source Code Biol Med       Date:  2010-01-13

6.  Evidence for in vivo growth potential and vascular remodeling of tissue-engineered artery.

Authors:  Seung-Woo Cho; Il-Kwon Kim; Jin Muk Kang; Kang Won Song; Hong Sik Kim; Chang Hwan Park; Kyung Jong Yoo; Byung-Soo Kim
Journal:  Tissue Eng Part A       Date:  2009-04       Impact factor: 3.845

7.  Pulmonary artery banding in infants with complete atrioventricular canal.

Authors:  M L Epstein; J H Moller; K Amplatz; D M Nicoloff
Journal:  J Thorac Cardiovasc Surg       Date:  1979-07       Impact factor: 5.209

Review 8.  Right ventricle in pulmonary hypertension.

Authors:  Norbert F Voelkel; Ramesh Natarajan; Jennifer I Drake; Herman J Bogaard
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

9.  Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Authors:  Steven H Abman; Georg Hansmann; Stephen L Archer; D Dunbar Ivy; Ian Adatia; Wendy K Chung; Brian D Hanna; Erika B Rosenzweig; J Usha Raj; David Cornfield; Kurt R Stenmark; Robin Steinhorn; Bernard Thébaud; Jeffrey R Fineman; Titus Kuehne; Jeffrey A Feinstein; Mark K Friedberg; Michael Earing; Robyn J Barst; Roberta L Keller; John P Kinsella; Mary Mullen; Robin Deterding; Thomas Kulik; George Mallory; Tilman Humpl; David L Wessel
Journal:  Circulation       Date:  2015-11-03       Impact factor: 29.690

10.  Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Authors:  Ralph Theo Schermuly; Klaus Peter Kreisselmeier; Hossein Ardeschir Ghofrani; Arun Samidurai; Soni Pullamsetti; Norbert Weissmann; Christian Schudt; Leander Ermert; Werner Seeger; Friedrich Grimminger
Journal:  Circ Res       Date:  2004-03-18       Impact factor: 17.367

View more
  1 in total

1.  Impact of Isolated Tricuspid Valve Repair on Right Ventricular Remodelling in an Adult Congenital Heart Disease Population.

Authors:  Roberto Marsico; Vito Domenico Bruno; Pierpaolo Chivasso; Anna Baritussio; Filippo Rapetto; Gustavo A Guida; Umberto Benedetto; Massimo Caputo
Journal:  Front Cardiovasc Med       Date:  2017-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.